person · Reporting owner
French Glendon E. III
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EDAP TMS SAEDAP · Entity 6325 | Director | January 01, 2026 | January 10, 2026 |
| Pulmonx CorpLUNG · Entity 2359 | Director · President and CEO | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EDAP TMS SA
Report date January 01, 2026 · Filed January 10, 2026
This filing explicitly reported no securities owned.
Pulmonx Corp
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,175,720 |
Reported balance
After 2026-09-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-01 · Sale · Disposed 4,098 · Balance 1,175,720 F1: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2023. F2: Includes 1,656 shares acquired by the reporting person under the Issuer's 2020 Employee Stock Purchase Plan on August 14, 2026. |
| Common StockSEC Table I · non-derivative | Direct | 1,137,936 |
Reported balance
After 2026-09-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-01 · Sale · Disposed 37,784 · Balance 1,137,936 F3: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on December 1, 2025. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 918,198 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 918,198 F4: The shares are held by the Glendon E French & Gayle French Trustees French Family Rev Trust UA DTD 08/29/2012, of which the reporting person and his spouse are trustees and beneficiaries. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2023.
F2: Includes 1,656 shares acquired by the reporting person under the Issuer's 2020 Employee Stock Purchase Plan on August 14, 2026.
F3: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on December 1, 2025.
F4: The shares are held by the Glendon E French & Gayle French Trustees French Family Rev Trust UA DTD 08/29/2012, of which the reporting person and his spouse are trustees and beneficiaries.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2022 Filed Aug 22, 2022 21:45 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 50,000 | $20.59 | $1,029,500.00 |
DisclosureSEC source: 0001209191-22-047057 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,055,884 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.02 to $21.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: Includes 890 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on August 15, 2022. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 22:02 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 1,525 | $18.05 | $27,526.25 |
DisclosureSEC source: 0001209191-22-034297 · doc4.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,104,994 F2 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on March 1, 2022. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 22:02 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 998 | $18.05 | $18,013.90 |
DisclosureSEC source: 0001209191-22-034297 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,106,519 F1 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on June 1, 2021. Read SEC document |
| May 16, 2022 Filed May 18, 2022 22:11 UTC | Pulmonx Corp LUNG · Entity 2359 | GiftCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-030215 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,107,517 F1 · kind: Represents a charitable donation of the shares of the Issuer made by the Reporting Person. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:03 UTC | Pulmonx Corp LUNG · Entity 2359 | GrantEmployee Stock Option (right to buy) · Derivative | 154,600 | $0.00 Strike: $26.56 | $0.00 |
DisclosureSEC source: 0001209191-22-015792 · doc4.xml · derivative · entry 3 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,600 Underlying: Common Stock · 154,600 shares Expires 2032-02-29 F3 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on March 1, 2022. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:03 UTC | Pulmonx Corp LUNG · Entity 2359 | GrantCommon Stock | 69,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-015792 · doc4.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,132,517 F2 · shares: Represents grant of Restricted Stock Units payable solely in common stock of the Issuer that vest over four years in equal quarterly installments beginning on March 1, 2022. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:03 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 1,132 | $25.91 | $29,330.12 |
DisclosureSEC source: 0001209191-22-015792 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,062,817 F1 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on June 1, 2021. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 22:45 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 3,939 | $27.13 | $106,865.07 |
DisclosureSEC source: 0001209191-22-011844 · doc4.xml · nonDerivative · entry 3 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,063,949 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.04 to $27.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 18, 2022 Filed Feb 22, 2022 22:45 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 8,561 | $26.81 | $229,520.41 |
DisclosureSEC source: 0001209191-22-011844 · doc4.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,067,888 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.01 to $27.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:45 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 12,500 | $27.22 | $340,250.00 |
DisclosureSEC source: 0001209191-22-011844 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,076,449 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.87 to $27.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 21, 2022 Filed Jan 24, 2022 22:41 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 200 | $24.73 | $4,946.00 |
DisclosureSEC source: 0001209191-22-004643 · doc4.xml · nonDerivative · entry 4 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,088,949 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 21, 2022 Filed Jan 24, 2022 22:41 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 187 | $24.72 | $4,622.64 |
DisclosureSEC source: 0001209191-22-004643 · doc4.xml · nonDerivative · entry 3 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,089,149 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 21, 2022 Filed Jan 24, 2022 22:41 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 12,113 | $24.22 | $293,376.86 |
DisclosureSEC source: 0001209191-22-004643 · doc4.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,089,336 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.71 to $24.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 20, 2022 Filed Jan 24, 2022 22:41 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 12,500 | $25.98 | $324,750.00 |
DisclosureSEC source: 0001209191-22-004643 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,101,449 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.33 to $26.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 16, 2021 Filed Dec 18, 2021 01:06 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 6,598 | $31.91 | $210,542.18 |
DisclosureSEC source: 0001209191-21-070463 · doc4.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,113,949 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.46 to $32.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 16, 2021 Filed Dec 18, 2021 01:06 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 18,402 | $30.74 | $565,677.48 |
DisclosureSEC source: 0001209191-21-070463 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,120,547 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.43 to $31.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 01, 2021 Filed Dec 4, 2021 00:11 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 1,421 | $32.73 | $46,509.33 |
DisclosureSEC source: 0001209191-21-067999 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,138,949 F1 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on June 1, 2021. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 23:44 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 100 | $37.09 | $3,709.00 |
DisclosureSEC source: 0001209191-21-066199 · doc4.xml · nonDerivative · entry 4 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,105,370 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 23:44 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 100 | $37.08 | $3,708.00 |
DisclosureSEC source: 0001209191-21-066199 · doc4.xml · nonDerivative · entry 3 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,105,470 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 23:44 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 13,209 | $36.47 | $481,732.23 |
DisclosureSEC source: 0001209191-21-066199 · doc4.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,105,570 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.06 to $37.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 18, 2021 Filed Nov 22, 2021 23:44 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 11,591 | $35.40 | $410,321.40 |
DisclosureSEC source: 0001209191-21-066199 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,118,779 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.01 to $35.93, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 21, 2021 Filed Oct 22, 2021 23:11 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 8,597 | $39.99 | $343,794.03 |
DisclosureSEC source: 0001209191-21-061431 · doc4.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,130,370 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.75 to $40.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 21, 2021 Filed Oct 22, 2021 23:11 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 16,403 | $39.62 | $649,886.86 |
DisclosureSEC source: 0001209191-21-061431 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,138,967 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.73 to $39.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 20, 2021 Filed Sep 21, 2021 00:45 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 1,700 | $38.01 | $64,617.00 |
DisclosureSEC source: 0001209191-21-056974 · doc4.xml · nonDerivative · entry 3 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Glendon E. French III Children's Irrevocable Trust on December 15, 2020, as amended August 20, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.875 to $38.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · ownership.nature: The shares are directly held by the Glendon E. French III Children's Irrevocable Trust dated 11-17-98 for which the Reporting Person is a trustee. Read SEC document |
| September 20, 2021 Filed Sep 21, 2021 00:45 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 21,871 | $37.31 | $816,007.01 |
DisclosureSEC source: 0001209191-21-056974 · doc4.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,700 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Glendon E. French III Children's Irrevocable Trust on December 15, 2020, as amended August 20, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.81 to $37.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · ownership.nature: The shares are directly held by the Glendon E. French III Children's Irrevocable Trust dated 11-17-98 for which the Reporting Person is a trustee. Read SEC document |
| September 16, 2021 Filed Sep 21, 2021 00:45 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 25,000 | $38.86 | $971,500.00 |
DisclosureSEC source: 0001209191-21-056974 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,155,370 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.26 to $39.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 01, 2021 Filed Sep 3, 2021 21:50 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 1,421 | $40.09 | $56,967.89 |
DisclosureSEC source: 0001209191-21-054857 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,180,370 F1 · kind: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units granted on June 1, 2021. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 22:31 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 25,000 | $36.63 | $915,750.00 |
DisclosureSEC source: 0001209191-21-053007 · doc4.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,181,791 F3 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.34 to $37.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · balance_after: Includes 57 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on August 13, 2021. Read SEC document |
| August 19, 2021 Filed Aug 23, 2021 22:31 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 1,000 | $36.59 | $36,590.00 |
DisclosureSEC source: 0001209191-21-053007 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 23,571 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Glendon E. French III Children's Irrevocable Trust on December 15, 2020. F2 · ownership.nature: The shares are directly held by the Glendon E. French III Children's Irrevocable Trust dated 11-17-98 for which the Reporting Person is a trustee. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 23:48 UTC | Pulmonx Corp LUNG · Entity 2359 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,375 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001209191-21-047261 · doc4.xml · derivative · entry 8 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,249 Underlying: Common Stock · 4,375 shares Expires 2030-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The shares subject to the option are immediately exercisable and vest in 48 equal monthly installments beginning on August 28, 2020, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 23:48 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 807 | $38.90 | $31,392.30 |
DisclosureSEC source: 0001209191-21-047261 · doc4.xml · nonDerivative · entry 7 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 24,571 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Glendon E. French III Children's Irrevocable Trust on December 15, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.75 to $39.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F5 · ownership.nature: The shares are directly held by the Glendon E. French III Children's Irrevocable Trust dated 11-17-98 for which the Reporting Person is a trustee. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 23:48 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 100 | $38.20 | $3,820.00 |
DisclosureSEC source: 0001209191-21-047261 · doc4.xml · nonDerivative · entry 6 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 25,378 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Glendon E. French III Children's Irrevocable Trust on December 15, 2020. F5 · ownership.nature: The shares are directly held by the Glendon E. French III Children's Irrevocable Trust dated 11-17-98 for which the Reporting Person is a trustee. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 23:48 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 93 | $37.53 | $3,490.29 |
DisclosureSEC source: 0001209191-21-047261 · doc4.xml · nonDerivative · entry 5 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 25,478 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Glendon E. French III Children's Irrevocable Trust on December 15, 2020. F5 · ownership.nature: The shares are directly held by the Glendon E. French III Children's Irrevocable Trust dated 11-17-98 for which the Reporting Person is a trustee. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 23:48 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 12,500 | $38.73 | $484,125.00 |
DisclosureSEC source: 0001209191-21-047261 · doc4.xml · nonDerivative · entry 4 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,206,734 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 23:48 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 11,163 | $38.86 | $433,794.18 |
DisclosureSEC source: 0001209191-21-047261 · doc4.xml · nonDerivative · entry 3 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,219,234 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.20 to $39.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 23:48 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 1,337 | $37.61 | $50,284.57 |
DisclosureSEC source: 0001209191-21-047261 · doc4.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,230,397 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.14 to $38.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 15, 2021 Filed Jul 19, 2021 23:48 UTC | Pulmonx Corp LUNG · Entity 2359 | Exercise / conversionCommon Stock | 4,375 | $2.20 | $9,625.00 |
DisclosureSEC source: 0001209191-21-047261 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,231,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 22:26 UTC | Pulmonx Corp LUNG · Entity 2359 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 4,375 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001209191-21-042216 · doc4.xml · derivative · entry 5 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,624 Underlying: Common Stock · 4,375 shares Expires 2030-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option are immediately exercisable and vest in 48 equal monthly installments beginning on August 28, 2020, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 22:26 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 1,000 | $42.68 | $42,680.00 |
DisclosureSEC source: 0001209191-21-042216 · doc4.xml · nonDerivative · entry 4 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 25,571 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Glendon E. French III Children's Irrevocable Trust on December 15, 2020. F5 · ownership.nature: The shares are directly held by the Glendon E. French III Children's Irrevocable Trust dated 11-17-98 for which the Reporting Person is a trustee. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 22:26 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 4,929 | $43.47 | $214,263.63 |
DisclosureSEC source: 0001209191-21-042216 · doc4.xml · nonDerivative · entry 3 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,227,359 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.27 to $43.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 22:26 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 20,071 | $42.83 | $859,640.93 |
DisclosureSEC source: 0001209191-21-042216 · doc4.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,232,288 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.27 to $43.22, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 22:26 UTC | Pulmonx Corp LUNG · Entity 2359 | Exercise / conversionCommon Stock | 4,375 | $2.20 | $9,625.00 |
DisclosureSEC source: 0001209191-21-042216 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,252,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2021 Filed Jun 12, 2021 00:15 UTC | Pulmonx Corp LUNG · Entity 2359 | GrantEmployee Stock Option (right to buy) · Derivative | 103,700 | $0.00 Strike: $43.40 | $0.00 |
DisclosureSEC source: 0001209191-21-040070 · doc4.xml · derivative · entry 3 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,700 Underlying: Common Stock · 103,700 shares Expires 2031-05-31 F4 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on June 1, 2021. Read SEC document |
| June 01, 2021 Filed Jun 12, 2021 00:15 UTC | Pulmonx Corp LUNG · Entity 2359 | GrantCommon Stock | 45,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040070 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,247,984 F1 · shares: Represents grant of Restricted Stock Units payable solely in common stock of the Issuer that vest over four years in equal quarterly installments beginning on June 1, 2021. F2 · balance_after: Includes 2,500 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan on May 24, 2021. Read SEC document |
| May 20, 2021 Filed May 21, 2021 21:25 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 1,000 | $40.75 | $40,750.00 |
DisclosureSEC source: 0001209191-21-035021 · doc4.xml · nonDerivative · entry 3 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 26,571 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Glendon E. French III Children's Irrevocable Trust on December 15, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.54 to $41.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F6 · ownership.nature: The shares are directly held by the Glendon E. French III Children's Irrevocable Trust dated 11-17-98 for which the Reporting Person is a trustee. Read SEC document |
| May 20, 2021 Filed May 21, 2021 21:25 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 19,941 | $42.19 | $841,310.79 |
DisclosureSEC source: 0001209191-21-035021 · doc4.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,199,884 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.85 to $42.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 20, 2021 Filed May 21, 2021 21:25 UTC | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 5,059 | $41.01 | $207,469.59 |
DisclosureSEC source: 0001209191-21-035021 · doc4.xml · nonDerivative · entry 1 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,219,825 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.71 to $41.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 20, 2021 Filed Dec 4, 2021 00:08 UTC Amendment | Pulmonx Corp LUNG · Entity 2359 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0001209191-21-067997 · doc4a.xml · derivative · entry 4 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,999 Underlying: Common Stock · 10,000 shares Expires 2030-08-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option are immediately exercisable and vest in 48 equal monthly installments beginning on August 28, 2020, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| May 20, 2021 Filed Dec 4, 2021 00:08 UTC Amendment | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 19,941 | $42.19 | $841,310.79 |
DisclosureSEC source: 0001209191-21-067997 · doc4a.xml · nonDerivative · entry 3 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,234,884 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.85 to $42.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 20, 2021 Filed Dec 4, 2021 00:08 UTC Amendment | Pulmonx Corp LUNG · Entity 2359 | SaleCommon Stock | 5,059 | $41.01 | $207,469.59 |
DisclosureSEC source: 0001209191-21-067997 · doc4a.xml · nonDerivative · entry 2 French Glendon E. III · CIK 0001805624 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,254,825 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.71 to $41.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.